Justin M Balko

List of Publications by Year
in descending order

115 papers	14,652 citations	44069 48 h-index	36028 97 g-index
121 all docs	121 docs citations	121 times ranked	21121 citing authors

#	Article	IF	Citations
1	Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews Clinical Oncology, 2022, 19, 254-267.	27.6	360
2	Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Frontiers in Immunology, 2022, 13, 844866.	4.8	68
3	Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype. Cancer Research, 2022, 82, PD3-04-PD3-04.	0.9	0
4	Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. Cancer Research, 2022, 82, P1-04-03-P1-04-03.	0.9	0
5	Abstract P4-04-07: Progesterone promotes immunomodulation and tumor development in the murine mammary gland. Cancer Research, 2022, 82, P4-04-07-P4-04-07.	0.9	0
6	Primed for toxicity: CD4+ TÂcells and immune checkpoint inhibitors. Med, 2022, 3, 155-156.	4.4	3
7	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. Cancer Research Communications, 2022, 2, 286-292.	1.7	2
8	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunology Research, 2022, 10, 829-843.	3.4	12
9	Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer. Breast Cancer Research, 2022, 24, .	5.0	2
10	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clinical Infectious Diseases, 2021, 72, e835-e843.	5.8	103
11	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitorâ€“Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discovery, 2021, 11, 614-625.	9.4	145
12	Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. Journal of Controlled Release, 2021, 330, 1118-1129.	9.9	58
13	Abstract PS4-19: Evaluation of tumor-specific MHC-II expression as a biomarker. , 2021, , .		0
14	Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues. Journal of Visualized Experiments, 2021, , .	0.3	2
15	Progesterone promotes immunomodulation and tumor development in the murine mammary gland. , 2021, 9, e001710.		12
16	Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.. Journal of Clinical Oncology, 2021, 39, 1091-1091.	1.6	5
17	Abstract NG15: Progesterone-mediated immune evasion in breast cancer. , 2021, , .		0
18	Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Research and Treatment, 2021, 190, 5-17.	2.5	16

#	Article	IF	Citations
19	RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets. Circulation Research, 2021, 129, 451-453.	4.5	4
20	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Antiâ€“PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clinical Cancer Research, 2021, 27, 5299-5306.	7.0	39
21	Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Instituteâ€“Designated Comprehensive Cancer Center. Oncologist, 2021, 26, e1962-e1970.	3.7	11
22	Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms. Breast Cancer Research, 2021, 23, 96.	5.0	6
23	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nature Communications, 2021, 12, 6276.	12.8	89
24	906â€…Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme. , 2021, 9, A951-A951.		0
25	318â€…Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance. , 2021, 9, A342-A342.		1
26	Pharmacological Activation of cGAS for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 753472.	4.8	13
27	Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. ACS Nano, 2020, 14, 651-663.	14.6	49
28	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncology, The, 2020, 21, e398-e404.	10.7	74
29	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clinical Cancer Research, 2020, 26, 5668-5681.	7.0	37
30	Demographic Factors Associated with Toxicity in Patients Treated with Antiâ€“Programmed Cell Death-1 Therapy. Cancer Immunology Research, 2020, 8, 851-855.	3.4	37
31	Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer. OncoImmunology, 2020, 9, 1758547.	4.6	12
32	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology, 2020, 86, 1778-1789.	2.4	34
33	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine, 2020, 12, .	12.4	46
34	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€Ł1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	142
35	Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma. , 2020, 8, e000282.		95
36	MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight, 2020, 5, .	5.0	22

#	Article	IF	Citations
37	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to antiâ€“PD-1 immunotherapy. Journal of Clinical Investigation, 2020, 130, 2570-2586.	8.2	134
38	MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression. , 2020, 3, 603-612.		15
39	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	30.7	133
40	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. Npj Breast Cancer, 2019, 5, 34.	5.2	55
41	Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1. Current Breast Cancer Reports, 2019, 11, 217-227.	1.0	7
42	If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer, 2019, 5, 37.	5.2	132
43	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	5.2	31
44	Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nature Nanotechnology, 2019, 14, 269-278.	31.5	406
45	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		237
46	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		2
47	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	12.8	252
48	Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. Oncologist, 2019, 24, 872-876.	3.7	38
49	Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?. Clinical Cancer Research, 2019, 25, 1452-1454.	7.0	33
50	Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. Cancer Research, 2019, 79, 171-182.	0.9	57
51	Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. Clinical Cancer Research, 2019, 25, 2392-2402.	7.0	282
52	Role of JAK-STAT Pathway in Cancer Signaling. , 2019, , 311-319.		16
53	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clinical Cancer Research, 2019, 25, 771-783.	7.0	29
54	Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).. Journal of Clinical Oncology, 2019, 37, 9564-9564.	1.6	0

#	Article	IF	Citations
55	A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?. Cancer Discovery, 2018, 8, 143-145.	9.4	15
56	DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nature Communications, 2018, 9, 248.	12.8	181
57	Biomarkers for assessing the effectiveness of immunotherapy in breast cancer. Biomarkers in Medicine, 2018, 12, 97-100.	1.4	1
58	PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3KÎ± Inhibitors. Clinical Cancer Research, 2018, 24, 1426-1435.	7.0	27
59	Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. Scientific Reports, 2018, 8, 4899.	3.3	91
60	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. OncoImmunology, 2018, 7, e1438106.	4.6	54
61	Emerging biomarkers for cancer immunotherapy in melanoma. Seminars in Cancer Biology, 2018, 52, 207-215.	9.6	42
62	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncology, The, 2018, 19, 1579-1589.	10.7	742
63	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncology, 2018, 4, 1721.	7.1	1,625
64	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Antiâ€“PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 5250-5260.	7.0	116
65	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. Npj Breast Cancer, 2018, 4, 10.	5.2	95
66	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight, 2018, 3, .	5.0	128
67	MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.. Journal of Clinical Oncology, 2018, 36, 180-180.	1.6	10
68	A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	7.0	268
69	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. Molecular and Cellular Proteomics, 2017, 16, 1705-1717.	3.8	56
70	Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. OncoImmunology, 2017, 6, e1305535.	4.6	56
71	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Molecular Cancer Research, 2017, 15, 259-268.	3.4	40
72	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449

#	Article	IF	Citations
73	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications, 2017, 8, 606.	12.8	89
74	Association of FGFR1 with ERÎ± Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clinical Cancer Research, 2017, 23, 6138-6150.	7.0	94
75	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine, 2017, 9, .	12.4	91
76	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	4.3	530
77	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	4.3	469
78	ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. Breast Cancer Research, 2017, 19, 105.	5.0	23
79	Molecular characterization of immune-related severe adverse events (irSAE).. Journal of Clinical Oncology, 2017, 35, 3076-3076.	1.6	2
80	Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9517-9517.	1.6	2
81	CCL5 expression and tumor infiltrating immune cells in triple negative breast cancer.. Journal of Clinical Oncology, 2017, 35, 11553-11553.	1.6	0
82	Comparative analysis of the <scp>GNAQ</scp>,<scp>GNA</scp>11,<scp>SF</scp>3B1, and <scp>EIF</scp>1<scp>AX</scp> driver mutations in melanoma and across the cancer spectrum. Pigment Cell and Melanoma Research, 2016, 29, 470-473.	3.3	18
83	Maybe we don't know JAK?. Molecular and Cellular Oncology, 2016, 3, e1192713.	0.7	1
84	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research, 2016, 4, 959-967.	3.4	428
85	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582.	12.8	412
86	A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. Npj Genomic Medicine, 2016, 1, 15015.	3.8	50
87	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine, 2016, 8, 334ra53.	12.4	105
88	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	27.0	1,668
89	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research, 2016, 76, 305-318.	0.9	98
90	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research, 2016, 22, 1499-1509.	7.0	428

#	Article	IF	Citations
91	Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.. Journal of Clinical Oncology, 2016, 34, 105-105.	1.6	16
92	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. Cancer Research, 2015, 75, 405-414.	0.9	53
93	PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 142-148.	0.9	18
94	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. Cancer Discovery, 2014, 4, 232-245.	9.4	413
95	Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	7.0	529
96	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	3.7	94
97	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research, 2014, 16, 406.	5.0	267
98	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1202-1209.	1.6	159
99	SU2C phase Ib study of the PI3KÎ± inhibitor BYL719 with letrozole in ER+/HER2â€“ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2014, 32, 516-516.	1.6	2
100	Inhibition of polo-like kinase 1 (PLK1) in endocrine-resistant ER+ breast cancer.. Journal of Clinical Oncology, 2014, 32, 515-515.	1.6	0
101	Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.. Journal of Clinical Oncology, 2014, 32, 11089-11089.	1.6	1
102	Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discovery Medicine, 2014, 17, 275-83.	0.5	112
103	Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer. Cancer Research, 2013, 73, 6346-6358.	0.9	124
104	TGF-Î² inhibition enhances chemotherapy action against triple-negative breast cancer. Journal of Clinical Investigation, 2013, 123, 1348-1358.	8.2	495
105	Abstract PR05: P-REX1 creates a positive feedback loop to activate growth factor receptor/PI3K signaling. , 2013, , .		0
106	The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 221-226.	7.1	64
107	Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with aKRASMutation orFGFR1Gene Amplification. Molecular Cancer Therapeutics, 2012, 11, 2301-2305.	4.1	22
108	Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling. Journal of Biological Chemistry, 2012, 287, 257-267.	3.4	35

#	Article	IF	Citations
109	Molecular Signatures of Lung Cancer. Molecular Diagnosis and Therapy, 2012, 16, 1-6.	3.8	3
110	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine, 2012, 18, 1052-1059.	30.7	219
111	Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?. Breast Cancer Research and Treatment, 2011, 127, 65-67.	2.5	12
112	Do the genes tell us the path of most resistance?. Cancer Biology and Therapy, 2011, 11, 213-215.	3.4	0
113	MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. Cancer Biology and Therapy, 2009, 8, 522-530.	3.4	35
114	A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer, 2009, 9, 145.	2.6	26
115	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics, 2006, 7, 289.	2.8	66